BioCryst Pharmaceuticals (NASDAQ:BCRX) Now Covered by Wedbush

Wedbush initiated coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report issued to clients and investors on Tuesday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $15.00 price target on the biotechnology company’s stock. Wedbush’s target price would suggest a potential upside of 79.43% from the stock’s current price.

A number of other brokerages also recently issued reports on BCRX. Needham & Company LLC increased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. JMP Securities reissued a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday. Finally, Barclays increased their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, November 5th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $15.57.

BioCryst Pharmaceuticals Trading Up 1.0 %

NASDAQ BCRX opened at $8.36 on Tuesday. The firm’s fifty day moving average price is $8.07 and its two-hundred day moving average price is $7.85. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $9.50. The firm has a market capitalization of $1.73 billion, a P/E ratio of -13.70 and a beta of 1.75.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. During the same quarter in the prior year, the company posted $0.28 EPS. BioCryst Pharmaceuticals’s revenue was up 40.8% on a year-over-year basis. On average, research analysts anticipate that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Creative Planning grew its position in shares of BioCryst Pharmaceuticals by 5.9% during the third quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock worth $375,000 after purchasing an additional 2,734 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 1,322 shares during the period. Wealth Enhancement Advisory Services LLC increased its holdings in shares of BioCryst Pharmaceuticals by 44.5% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 17,344 shares of the biotechnology company’s stock valued at $132,000 after purchasing an additional 5,340 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 64.1% in the third quarter. China Universal Asset Management Co. Ltd. now owns 39,791 shares of the biotechnology company’s stock valued at $302,000 after purchasing an additional 15,544 shares during the period. Finally, Rice Hall James & Associates LLC increased its holdings in shares of BioCryst Pharmaceuticals by 4.0% in the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after purchasing an additional 84,102 shares during the period. 85.88% of the stock is owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.